365.81

1.46% -5.43

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $365.81, with a volume of 363.52K. It is down -1.46% in the last 24 hours and up +17.09% over the past month. Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Previous Close:

$371.24

Open:

$375

24h Volume:

363.52K

Relative Volume:

1.17

Market Cap:

$10.78B

Revenue:

$417.30M

Net Income/Loss:

$225.03M

P/E Ratio:

48.90

EPS:

7.4815

Net Cash Flow:

$237.38M

1W Performance:

-2.47%

1M Performance:

+17.09%

6M Performance:

+39.94%

1Y Performance:

+144.30%

1-Day Range:

$355.55

$375.00

1-Week Range:

$355.55

$382.13

52-Week Range:

$130.50

$382.54

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

295

Twitter

@KrystalBiotech

Next Earnings Date

2026-08-03

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	365.81	10.78B	417.30M	225.03M	237.38M	7.4815
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Jul 09, 2026

Krystal Biotech focuses on gene-based dermatology treatments as investors watch long-term growth - ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026